Search Results
267 Results for 'Therapeutics & Vaccines'
PAGE 5 OF 11
Technology
High Titer Recombinant Influenza Viruses With Enhanced Replication In Mdck Or Vero Cells Or Eggs
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P130287US02
Technology
Alkylphosphocholine Analogs For Multiple Myeloma Imaging And Therapy
The inventors have discovered that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells, as compared to non-tumor cells. The inventors have further demonstra...
Learn More
Learn More
Chorom Pak, Jamey Weichert, Mario Otto, Roberta Marino, Fotios Asimakopoulos, Benjamin Titz, Kevin Kozak | P150207US03
Technology
Syndecan Peptides And Polypeptides As Inhibitors Of Vegfr2 And Vla-4
Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of α4β1 integrin (also known as very...
Learn More
Learn More
Alan Rapraeger, Oisun Jung | P150222US02
Technology
Inhibitors Of Collagen Prolyl 4-Hydroxylase
The invention provides biheteroaryl dicarboxylates and esters, and salts thereof which are useful generally as modulators of CP4H activity, more particularly as inhibitors of CP4H, or further as chemi...
Learn More
Learn More
Ronald Raines, James Vasta | P150092US02
Technology
Influenza Virus Replication By Inhibiting Microrna Lec7c Binding To Influenza Viral Crna And Mrna
A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150345US02
Technology
Generation Of Infectious Influenza Viruses From Virus-Like Particles
Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann | P150373US02
Technology
Perivascular Drug Delivery System
The present technology provide compositions that are drug delivery systems for the sustained release of anti-stenotic drugs for the treatment and prevention of occlusion of blood vessels, particularly...
Learn More
Learn More
Lianwang Guo, K. Craig Kent, Shaoqin Gong, Xudong Shi, Guojun Chen | P160359US02
Technology
Amino Thiol Compounds And Compositions For Use In Conjunction With Cancer Therapy
The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are admi...
Learn More
Learn More
William Fahl, Daniel Peebles, Richard Copp | P04014US
Technology
1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D Compounds With A 1,1-dimethylpropyl Side C
This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced a...
Learn More
Learn More
Hector DeLuca, Rafal Sicinski, Lori Plum, Agnieszka Glebocka, Margaret Clagett-Dame | P06381US
Technology
(20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol And Its Uses
This invention discloses (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P07496US
Technology
(20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol And Its Uses
This invention discloses (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P07497US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P09210US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P09211US
Technology
2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Its Uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound e...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P09212US
Technology
2alpha-methyl And 2beta- Methyl Analogs Of 19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Their
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P09213US
Technology
2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol And Its Uses
This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Lori Plum, Bulli Padmaja Tadi, Margaret Clagett-Dame | P09214US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P09215US
Technology
Method Of Treating Multiple Sclerosis
A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a pre-determined dose of UV-containing light from a ...
Learn More
Learn More
Hector DeLuca, Bryan Becklund | P100177US03
Technology
Diastereomers Of 2-Methylene-19-Nor-22-Methyl-1alpha,25-Dihydroxyvitamin D3
Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are use...
Learn More
Learn More
Hector DeLuca, Agnieszka Flores, Pawel Grzywacz, Margaret Clagett-Dame, Lori Plum, Hazel Holden, James Thoden | P100048US03
Technology
Peptide-Nanoparticle Conjugates
Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of β-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and meth...
Learn More
Learn More
Seungpyo Hong, Woo-jin Jeong | P200080US02
Technology
Synthesis Of Small Molecule Histone Deacetylase 6 Degraders, Compounds Formed Thereby, And Pharmaceutical Compositions Containing Them
Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; ...
Learn More
Learn More
Weiping Tang, Ka Yang, Hao Wu, Zhongrui Zhang | P180321US05
Technology
Mini-Intronic Plasmid Dna Vaccines In Combination With Lag3 Blockade
It is disclosed herein that (a) an anti-tumor DNA vaccine delivered using a MIP DNA vector is a less effective tumor treatment than the corresponding anti-tumor DNA vaccine delivered using a conventio...
Learn More
Learn More
Douglas McNeel, Viswa Colluru | P150088US02
Technology
(20s)-2-Methylene-19-Nor-22-Dimethyl-1alpha,25-Dihydroxyvitamin D3 And (20r)-2-Methylene-19-Nor-22-Dimethyl-1alpha,25-Dihydroxyvitamin D3
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are usef...
Learn More
Learn More
Hector DeLuca, Agnieszka Flores, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P100057US02
Technology
Vaccines Comprising Mutant Attenuated Influenza Viruses
The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant ...
Learn More
Learn More
Yoshihiro Kawaoka, Shinji Watanabe, Tokiko Watanabe | P100251US02
Technology
Engineered Botulinum Neurotoxin C1 With Selective Substrate Specificity
An isolated polypeptide comprising a botulinum neurotoxin C1 light chain having a modified amino acid sequence relative to the sequence of a wild-type botulinum neurotoxin C1 light chain is disclosed....
Learn More
Learn More
Meyer Jackson, Dongsheng Wang | P100145US02